





MAY 11, 1997

IBM'S DEEP BLUE DEFEATS HUMAN CHAMPION GARY KASPAROV








208,168,199,381,979,984,699,478,633,344,862, 770,286,522,453,884,530,548,425,639,456,820, 927,419,612,738,015,378,525,648,451,698,519, 643,907,259,916,015,628,128,546,089,888,314, 427,129,715,319,317,557,736,620,397,247,064, 840,935

٠


MAR 15, 2016


GOOGLE DEEPMIND'S ALPHAGO DEFEATS HUMAN CHAMPION LEE SEDOL















Machine Learning Capabilities & Applications











AI for Health Care Delivery



- 1. Anticipating patients' current and future needs
- 2. Developing personalized care plans
- 3. Creating decision support tools and automation for clinicians

BIG DATA: MORE PERSONALIZED, PROACTIVE AND EFFICIENT CARE

HEATH-









5



HEATH:





BIG DATA: MORE PERSONALIZED, PROACTIVE AND EFFICIENT CARE

INCALTH -



Health Care AI Hype · A recent search identified over 5,000 papers related to applications of AI and Machine Learning in health care. Many of these papers claim that algorithms perform as well or better than human experts · Only about a dozen of these studies include prospective validation and/or measurement of how use of the algorithm impacts health outcomes "There has been remarkably little prospective validation for tasks that machines could perform to halp clinicians or predict clinical outcomes that would be useful for health systems, and even less for point-centered cligarithms. The field is certainly high on promise and relatively low on data and proof" Traje thtms://doi.org/10.1031/d1391-016-0300-7

-0.00

FDA-Approved AI Tools

The FDA is focused on clearly defining and regulating "software-as-a-medical-device,".

On January 8, 2019, the FDA published a new Software Precertification Pilot Program and a regulatory framework explaining how it plans to regulate the next generation of digital health services, particularly those that leverage AI and ML to support decision-making.

This will allow companies to make "minor changes to its devices without having to make submissions each time."

Fast-track regulatory approval opens new commercial pathways for over 70 AI imaging & diagnostics companies that have raised equity financing since 2013, accounting for a total of 119 deals.



FDA-Approved AI Tools In 2017 the FDA approved two AI devices:


Company	FDA Approval	Indication	
Alivecor	November 2017	Afib detection via Apple Watch	
Arterys	January 2017	MRI heart interpretation	
In 2018 there were 1	12 AI devices approved:		
Company	FDA Approval	Indication	
Apple	September 2018	Atrial fibrillation detection	
Aidoc	August 2018	CT brain bleed diagnosis	
iCAD	August 2018	Breast density via mammography	
Zebra Medical	July 2018	Coronary calcium scoring	
Bay Labs	June 2018	Echocardiogram EF determination	
Neural Analytics	May 2018	Device for paramedic stroke diagnosis	
ldx	April 2018	Diabetic retinopathy diagnosis	
Icometrix	April 2018	MRI brain interpretation	
Imagen	March 2018	X-ray wrist fracture diagnosis	
Viz.ai	February 2018	CT stroke diagnosis	
Arterys	February 2018	Liver and lung cancer (MRI, CT) diagnosis	
MaxQ-Al	January 2018	CT brain bleed diagnosis	




7















POPULATION MANAGEMENT & PERSONALIZATION: HEALTHY STONES

- Recurrence risk model identifies high risk patients to enroll in the
- healthy stones program Time to recurrence model prioritizes patients within the high risk group
- ▶ Recurrence Risk Model: AUCROC = 0.83
- ► Time to Recurrence Model: C-statistic: 0.79









- Decrease readmissions
- Increase preemptive outreach






(**)	TITLE MARKED	
_		
	CONTRACTOR OF A	
	Annual Annual Annual Annual	
	The second se	
10 00 040		
	And States and A	
	the second secon	
	Territory (Second Second Secon	








202212 **DECISION SUPPORT:** Computer Vision

10271

Algorithmic Justice

Machine learning models predict exactly what they have
been trained to predict, their forecasts are only as good as the data

Data is not value free but rather a product of the systems that generate and collect the data



Algorithmic Justice

2.44 -----

(Arpey et al. 2017)

-0.00

- Identify the target population and select training and testing sets accordingly Build and test algorithms in socioeconomically diverse health care •
- systems Ensure that key variables, such as race/ethnicity, language, and .
- social determinants of health, are being captured and included in algorithms when appropriate Test algorithms for potential discriminatory behavior throughout data
- . processing Develop feedback loops to monitor and verify output and validity
- .

Gianfrancesco+ (2018)

